Venus Remedies Ltd

Venus Remedies Ltd has seen its investment rating upgraded from Hold to Buy, driven primarily by an improved valuation profile and robust financial performance. The company’s micro-cap status, combined with strong operational metrics and technical signals, underpins this positive reassessment by MarketsMOJO as of 5 August 2026.

Venus Remedies Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, supported by robust financial metrics and a compelling growth trajectory. This micro-cap pharmaceutical player now presents a more enticing price proposition relative to its historical averages and peer group, signalling renewed investor interest and potential upside.

At Rs 1,509.3, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 3.99% on 28 Jul 2026, with unfilled sell orders and a frozen price that capped losses for the day.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 27 July 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite robust financial performance and impressive long-term returns, evolving market dynamics and technical signals have prompted a more cautious stance.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish trend. Despite a sharp decline in its share price over the past month, the stock’s long-term returns remain impressive, though recent technical indicators suggest a more cautious outlook for investors.

Venus Remedies Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 14 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 July 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 1,572.9, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 5% on 24 Jul 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

At Rs 1,686.8, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 5.0% on 21 Jul 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock.

Venus Remedies Ltd has undergone a significant valuation recalibration, moving from an expensive to a fair valuation grade, reflecting improved price attractiveness amid robust financial metrics and strong market performance. This shift, coupled with a recent upgrade to a Buy rating and a notable Mojo Score of 74.0, positions the micro-cap pharmaceutical player as a compelling proposition in the Pharmaceuticals & Biotechnology sector.

At Rs 1778.5, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 4.99% on 21 Jul 2026, with buyers queuing and no sellers willing to part with shares.

Venus Remedies Ltd., the Chandigarh-based pharmaceutical company specialising in injectable formulations, reported a robust performance for Q1 FY27, with net profit surging 139.27% year-on-year to ₹22.97 crores, despite a sequential decline of 51.64% from the exceptionally strong Q4 FY26. The company's shares rallied 3.25% to ₹1,780.00 following the results announcement, reflecting investor confidence in the sustained growth trajectory despite the quarter-on-quarter moderation.

At Rs 1681.5, sellers were still queuing — but there were no buyers willing to take the other side. Venus Remedies Ltd locked at its lower circuit of 5.0% on 20 Jul 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock.

Venus Remedies Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across technical indicators, valuation metrics, financial trends, and overall quality. The pharmaceutical company’s recent performance and market behaviour have prompted analysts to revise their outlook, signalling growing investor confidence in its prospects.

At Rs 1,895.6, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Venus Remedies Ltd locked at its upper circuit of 5.0% on 13 Jul 2026, with buyers queuing and no sellers willing to part with shares.

Venus Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade from Buy to Hold. Despite a robust share price rally and impressive returns relative to the Sensex, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have moved into expensive territory, signalling a reassessment of its price attractiveness among investors.